BETASERON® (interferon beta-1b) should be used with caution in patients with depression. Injection-site necrosis has been reported in 4% of patients in controlled trials. Patients should be advised of the importance of rotating injection sites...continue reading below
Why Early Treatment Matters
Studies suggest that MS causes damage in the early years of the disease.1,2
Whether you're newly diagnosed or have been living with MS, ask your doctor if
BETASERON® (interferon beta-1b) may be right for you. BETASERON is indicated for
the treatment of relapsing forms of multiple sclerosis to reduce the frequency of
clinical exacerbations.
How betaseron may help delay disease progression:
Early treatment with BETASERON helped delay
disease progression to clinically definite MS (CDMS) by over 50% overall compared
with the placebo group.8 So the sooner you start treating MS, the better. Ask your
healthcare provider if BETASERON may be right for you.
*Some restrictions apply. Please visit Affording BETASERON or call 1-800-788-1467 for more information. Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. As a condition precedent of the copayment support provided under this program, eg, copay refunds, participating patients and pharmacies are obligated to inform insurance companies and third-party payors of any benefits they receive and the value of this program, as required by contract or otherwise. Void where prohibited by law, taxed, or restricted. Patients enrolled in Bayer's Patient Assistance Program are not eligible.
INDICATIONS AND USAGE
BETASERON® (interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.
IMPORTANT SAFETY INFORMATION
BETASERON should be used with caution in patients with depression.
Injection-site necrosis has been reported in 4% of patients in controlled trials. Patients should be advised of the importance of rotating injection sites.
Severe hepatic injury, including cases of hepatic failure, has been reported. Patients should be monitored for liver enzyme elevations while taking BETASERON.
BETASERON should be used with caution in patients with seizure disorders or cardiac disease.
Female patients should be warned about the potential risk to pregnancy.
Cases of anaphylaxis have been reported rarely.
The most commonly reported adverse reactions are lymphopenia (low numbers of a certain kind of white blood cell), Injection-site reaction, asthenia (general weakness), flu-like symptom complex (flu syndrome and/or a combination of at least two Adverse Events from fever, chills, muscle aches, tiredness and sweating), headache and pain. Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms.
